1	Continuous positive ai	rway pressure but not Liraglutide-mediated weight loss
2	improves early cardiov	ascular disease in obstructive sleep apnea: Data from a
3	ra	indomized proof-of-concept study.
4	Cliona O'Donnell ^{1,2} , Shan	e Crilly ³ , Anne O'Mahony ¹ , Brian O'Riordan ³ , Mark Traynor ¹ ,
5	Rachael Gitau ² , Kenne	th McDonald ^{2,4} , Mark Ledwidge ² , Donal O'Shea ^{2,5} , David J.
6	Mur	phy ^{2,3} , Jonathan D. Dodd ^{2,3} Silke Ryan ^{1,2*}
7	¹ Pulmonary and Sleep Disor	ders Unit, St. Vincent's University Hospital, Dublin, Ireland,
8	² School of Medicine, Univer	rsity College Dublin, Ireland, ³ Department of Radiology, St.
9	Vincent's University Hospita	al, Dublin, Ireland, ⁴ Department of Cardiology, St. Vincent's
10	University Hospital, Dublin	Ireland, ⁵ Department of Endocrinology, St. Vincent's University
11	Hospital, Dublin, Ireland	
12	Short Title: CPAP improve	s early CV disease in sleep apnea
13	*Corresponding author:	Prof. Silke Ryan MD, PhD,
14		Dept. of Respiratory Medicine
15		St. Vincent's University Hospital,
16		Elm Park,
17		Dublin 4, IRELAND.
18		Tel: 353-1-221 3702
19		Fax: 353-1-269 7949.
20		E-mail: <u>silke.ryan@ucd.ie</u>
21 22 22	Word count: 7,920 (Tota)))
23 24	4,099 (with	out title page, abstract, references, tables, and figure legends)

25 Abstract

26	
27	Background: Obstructive sleep apnea (OSA) is an independent risk factor for cardiovascular
28	(CV) morbidity and mortality, but the benefit of continuous positive airway pressure (CPAP)
29	therapy is uncertain. However, most randomized-controlled trials have focused on the role of
30	CPAP in secondary prevention although there is growing evidence of a potential benefit on
31	early CV disease. Weight loss in combination with CPAP may be superior but is difficult to
32	achieve and maintain with conventional measures alone. The aim of this study was to gain
33	insights into the effect of CPAP on early atherosclerotic processes and to compare it to a
34	glucagon-like-peptide (GLP)-1-mediated weight loss regimen in OSA.
35	Methods: We performed a randomized proof-of-concept study (clinicaltrials.gov:
36	NCT04186494) comparing CPAP, a liraglutide-based weight loss regimen (Lir) alone or both
37	in combination for 24 weeks in 30 non-diabetic patients with moderate to severe OSA (50 \pm 7
38	years, 80% males, apnea-hypopnea index [AHI] 50±19/hr, body mass index [BMI] 35.0 ± 3
39	kg/m^2). Baseline characteristics were similar between groups. Beside extensive evaluation for
40	CV risk factors and endothelial function at baseline and end of study, subjects underwent
41	18F-fluorodeoxyglucose (FDG)-PET-CT for measurement of aortic wall inflammation
42	(target-to-background ratio [TBR]) and coronary CT angiography (CCTA) for semi-
43	automated coronary plaque analysis.
44	Results: CPAP alone and combination resulted in greater reduction in AHI than Lir alone at
45	24 weeks (mean difference -45/hr and -43/hr, respectively, vs -12/hr, p<0.05). Both Lir and
46	combination led to significant weight loss of $6\pm3\%$ and $4\pm4\%$, respectively. Despite CPAP
47	resulting in small weight gain, only the CPAP alone group demonstrated a significant
48	decrease in vascular inflammation (aortic wall TBR from 2.03±0.34 to 1.84±0.43, p 0.010)
49	associated with improvement in endothelial function and decrease in C-reactive protein.
50	Low-attenuation coronary artery plaque volume as marker of unstable plaque also decreased

- 51 with CPAP (from 571 ± 490 to 334 ± 185 mm³) and with combination therapy (from 401 ± 145 to
- 52 278 ± 126 mm³) but not with Lir.
- 53 **Conclusion:** These data suggest that CPAP therapy, but not GLP-1 mediated weight loss,
- 54 improves vascular inflammation and reduces low-attenuation coronary artery plaque volume
- 55 in OSA patients. These novel findings support the benefit of CPAP therapy in modifying
- 56 early CV disease.

57 Clinical Perspective

58 What is new?

59	٠	This is the first study comparing standard CPAP therapy to a GLP-1 mediated weight
60		loss regimen in obstructive sleep apnea (OSA).
61	•	The study utilized 18F-FDG PET CT and artificial intelligence-enabled coronary CT
62		quantification of coronary artery plaque subtypes to determine treatment effects on
63		early atherosclerotic disease processes.
64	What	are the clinical implications?
65	•	CPAP in contrast to GLP-1-mediated weight loss may improve early atherosclerotic
66		and potentially modifiable disease processes in obstructive sleep apnea (OSA).
67	•	These data support the benefit of CPAP in the primary prevention of cardiovascular
68		diseases in OSA.
69		

70 Non-standard Abbreviations and Acronyms

- OSA obstructive sleep apnea
- 72 CV cardiovascular
- CAD coronary artery disease
- CPAP continuous positive airway pressure
- RCT randomized controlled trial
- PET-CT positron emission tomography-computed tomography
- FDG fluoro2-deoxy-D-glucose
- CCTA coronary computed tomographic angiography
- CP calcified plaque
- NCP non-calcified plaque
- LD low density
- GLP glucagon like peptide
- AHI apnea/hypopnea index
- BMI body mass index
- ABPM ambulatory blood pressure measurement
- PSG polysomnpgraphy
- AASM American Academy of Sleep Medicine
- RHI reactive hyperemia index
- PAT peripheral arterial tone
- TBR target-to-background ratio
- CAC coronary artery calcium
- HbA1c glycosylated hemoglobin
- SpO₂ oxygen saturation
- ODI oxygen desaturation index

• TST90 - time spent with SpO₂<90% of total sleep time

97 **Introduction**

98	Obstructive sleep apnea (OSA) is a highly prevalent condition conveying a significant
99	public health burden ^{1,2} . Corroborated by numerous studies it has been identified as a
100	significant and potentially modifiable risk factor for the development and progression of
101	various cardiovascular (CV) diseases, such as coronary artery disease (CAD), hypertension,
102	heart failure and stroke leading to substantial morbidity and mortality ^{2,3} .
103	The benefit of continuous positive airway pressure (CPAP) therapy, the treatment of
104	choice for the majority of patients, on CV disease processes, remains uncertain and although
105	impacted by important methodological limitations, secondary prevention trials have failed to
106	demonstrate a significant modifying effect on CV outcomes ⁴⁻⁶ . However, various randomized
107	controlled trials (RCT) and meta-analyses have supported a benefit of CPAP on CV risk
108	factors such as blood pressure ^{7,8} , endothelial dysfunction ⁹ , arterial stiffness ¹⁰ , and circulating
109	inflammatory markers ^{11,12} and thus, CPAP may be particularly beneficial in the early stages
110	of CV disease processes. There is a lack of studies focusing on early atherosclerotic processes
111	in OSA and in the absence of definite primary prevention RCT's, which are an unrealistic
112	goal in the field, such studies may assist in the guidance of personalized treatments.
113	Advances in CV imaging techniques may help to fill this gap. The use of positron emission
114	tomography-computed tomographic (PET-CT) imaging with 18F-fluoro2-deoxy-D-glucose
115	(18F-FDG) to measure vascular inflammation is an emerging method of predicting CV
116	disease. In the largest cohort study to date comprising 932 cancer patients without a history
117	of CV disease, aortic wall uptake of 18F-FDG was the strongest predictor of a subsequent
118	vascular event ¹³ .



automated quantification of non-calcified (NCP) and low-density (LD NCP) plaques, which
have been shown to be stronger predictors of future cardiovascular events than calcified
plaques^{15,16}.

125 We hypothesized that CPAP improves early CV disease processes. To explore this 126 hypothesis and to inform the design of future large RCT's, we performed this proof-of-127 concept prospective RCT comparing CPAP versus a glucagon-like peptide (GLP)-1 128 (Liraglutide) -based weight loss regimen versus both in combination. This comparison was 129 chosen based on the work of Chirinos et al, who found that a combination of weight loss and 130 CPAP therapy may be superior to either treatment alone across a range of outcomes¹⁷. We 131 integrated the primary outcome determining early CV disease with various risk markers in 132 relation to inflammation, endothelial function, and blood pressure.

133 Methods

134 <u>Study Protocol</u>

135 This was a proof-of-concept, randomized, parallel, 24-week trial comparing the 136 effects of CPAP, a liraglutide-based weight loss regimen (Lir) or both in combination in 137 adults with newly diagnosed moderate to severe OSA (apnea/hypopnea index [AHI]>15/hr). 138 Eligible participants were aged 18-60 years, had a body-mass index (BMI) between 30-40 139 kg/m², and no history of diabetes, heart failure or unstable cardiovascular disease defined as 140 lack of cardiovascular event within the preceding 3 months. Detailed inclusion and exclusion 141 criteria are provided in Supplementary Table S1 and the trial design with outcome measures 142 is outlined in Supplementary Figure S1. Randomization was conducted using block design. 143 The study was approved by the Ethics Committee of St. Vincent's University Hospital and 144 registered with clinical trials.gov (NCT04186494). Participants gave written informed 145 consent.

146 Interventions

147	In the CPAP and combined-intervention groups, participants were initiated on CPAP
148	therapy according to the standard protocol in our center. Briefly, patients undergo an
149	education and mask fitting session with a clinical sleep nurse specialist before setup on auto-
150	PAP at home (AirSense 10, ResMed, UK). Adherence to CPAP therapy is monitored
151	remotely and subjects are followed up by the treating clinician and specialist nurse after 4-6
152	weeks. Pressure settings are adjusted according to the discretion of the treating clinician.
153	Participants in the Lir and combination groups received education about
154	administration of subcutaneous injections and specific guidance about Liraglutide. In
155	addition, counselling on diet and exercise was provided at 4 and 12 weeks. Advice was based
156	around accepted Irish public health guidelines following the food pyramid
157	recommendations ¹⁸ on portion sizes and food groups and current recommended weekly
158	exercise amounts of 150 minutes of moderate intensity exercise per week ¹⁹ . Subjects
159	commenced Liraglutide (Novo Nordisk, Bagsværd, Denmark) 0.6mg once daily at week 1,
160	increasing by 0.6mg weekly until the maximum dose of 3.0mg was achieved, which was then
161	continued for the 24-week intervention. Progress, adverse effects, and safety were monitored
162	routinely at 4 and 12 weeks or in between if required, and serum amylase levels were
163	checked monthly.
164	Study Assessments and End Points
165	All assessments were performed at baseline and at 24 weeks (Supplementary Figure
166	S1). Fasting blood samples for measurement of metabolic, biochemical, and inflammatory
167	parameters were obtained in the morning after overnight polysomnography (PSG). 24-hour
168	ambulatory blood pressure measurement (ABPM) was performed using WatchBP03 devices

- 169 (Microlife Corp., Taipei, Taiwan). Measurements were taken every 20 minutes during the
- 170 day and every 30 minutes at night-time. Non-dipping blood pressure status was defined as
- 171 <10% decline in systolic blood pressure from day to night.

172 Polysomnography (PSG)

173	Attended, in-laboratory PSG was performed using standard techniques
174	(SOMNOmedics, Randersacker, Germany) and analyzed according to the American
175	Academy of Sleep Medicine (AASM) 2.6 scoring criteria ²⁰ . An apnea was defined as a 90%
176	drop in airflow from baseline for >10 seconds. A hypopnea was defined as a drop in airflow
177	of >30% from baseline for >10 seconds, accompanied by an oxygen desaturation of 3% or an
178	arousal. Repeat PSG at 24 weeks was performed on CPAP for those randomized to this
179	treatment.
180	Endothelial Function
181	Evaluation of peripheral endothelial function via the EndoPAT 2000 device (Itamar
182	Medical, Israel) is a validated, FDA-approved method ²¹ . Endothelial function was expressed
183	as reactive hyperemia index (RHI) calculated as the ratio of the post-occlusion to pre-
184	occlusion peripheral arterial tone (PAT) amplitude of the tested arm, divided by the post-
185	occlusion to pre-occlusion ratio obtained in the control arm ²² . Measurements were performed
186	according to the manufacturer's instructions with a cut-off value of <1.69 defining endothelial
187	dysfunction.
188	<u>18F-FDG PET-CT</u>
189	All 18F-FDG PET-CT examinations were performed on a Siemens Biograph mCT
190	PET/CT system (Siemens Healthineers, Erlangen, Germany) in line with prior
191	recommendations ²³ (see Supplementary Methods). PET image analysis to measure aortic wall
192	vascular inflammation was performed in consensus by 2 radiologists blinded to all clinical
193	information, using dedicated PET-CT image viewing software (SyngoVia, Siemens
194	Healthineers, Erlangen, Germany) according to a previously validated methodology ^{24,25} .
195	Briefly, sequential circular regions of interest were placed across the aortic wall from the root
196	to the abdominal bifurcation on axial images, with total aorta $\mathrm{SUV}_{\mathrm{max}}$ calculated as the mean

197 of these individual measurements. A target-to-background ratio (TBR) was calculated by

- 198 dividing total aorta SUV_{max} by mediastinal blood pool activity (average of three
- 199 measurements of blood pool SUV_{max} made at the SVC on sequential slices).
- 200 Coronary Computed Tomography Angiography (CCTA) Protocol and Image Analysis
- 201 CCTA images were acquired on a 64-slice single-source CT scanner (Gemstone 750
- 202 HD, GE, Milwaukee, USA) according to standard CCTA protocols (see Supplementary
- 203 Methods). Coronary artery calcium (CAC) score was assessed using the Agatston score 26 .
- 204 Coronary arteries were visually assessed on a 15-segment basis by a cardiothoracic
- 205 radiologist. Quantitative assessment of atherosclerotic plaque subtypes was performed using
- 206 previously validated semiautomatic software (CVi42, Circle Cardiovascular Imaging Inc,
- 207 Calgary, Canada)²⁷ by one observer blinded to all clinical information (see Supplementary
- 208 Methods). Plaque volumes were measured for the following plaque subtypes: total plaque,
- 209 calcified plaque (CP), noncalcified plaque (NCP) and low-attenuation plaque (LD NCP)
- 210 defined by an attenuation of <30 Hounsfield units¹⁶. CCTA was performed at baseline in all
- 211 subjects. Ethical approval for follow-up CCTA was only granted for subjects with visible CV
- 212 disease at baseline due to concern of excess radiation exposure.
- 213 <u>Statistical Analysis</u>

214 This was an exploratory proof-of-concept study with the purpose of aiding the 215 planning of future larger RCT's. Therefore, all statistical analysis presented is for the purpose 216 of exploring signals in treatment differences between groups. Comparisons between groups 217 were performed via one-way ANOVA with post-hoc Bonferroni analysis or Chi-Square test 218 for categorical variables. Within-group changes were evaluated by paired T-tests. Univariate 219 Pearson correlation analysis was performed to assess the correlation between baseline and 220 OSA parameters and CV outcome variables. Statistical analysis was carried out using IBM 221 SPSS Statistics Version 27.

222 **Results**

223 <u>Baseline characteristics</u>

224	450 consecutive patients attending our Sleep Centre were screened of whom 53 met
225	the inclusion and exclusion criteria. 23 did not provide consent. As planned, 30 subjects were
226	enrolled and randomized. Baseline characteristics of the study population are provided in
227	Table 1. As expected for a clinical OSA population, there was a predominance of male,
228	middle-aged participants and most had severe OSA with an AHI of 50 ± 19 /hour. The groups
229	were similar with regards to demographic, anthropometric and clinical parameters. There was
230	no significant difference between the groups in 24-hour ABPM, glycosylated hemoglobin
231	(HbA1c) and fasting lipids. 9 patients were on statin treatment: 2 for previously established
232	but stable CV disease, and 7 for dyslipidemia as primary prevention.
233	Study Progress
234	All 30 patients completed the trial and are included in the final analysis
235	(Supplementary Figure S2). Of the 10 subjects commenced on CPAP therapy, one patient
236	crossed over to the Liraglutide arm due to intolerance of CPAP therapy. In each of the
237	Liraglutide and combination groups, one subject crossed over to the CPAP arm due to
238	gastrointestinal side effects with Liraglutide. Thus, the final dataset included n=11 in the
239	CPAP group, n=10 in the Liraglutide group and n=9 in the combination group. All groups
240	remained similar in all baseline characteristics (Supplementary table S2). Apart from those
241	having to stop Liraglutide, adherence to the pharmacological treatment was good as reported
242	by the subjects and by monitoring the contents of the pre-filled pens. Serum amylase was
243	monitored monthly as recommended for patients taking Liraglutide, and there was no
244	significant rise during the trial in any subject. Mean CPAP adherence in the CPAP group was
245	5.8 ± 1.4 hours per night, while adherence in the combination group was 4.7 ± 1.8 hours per
246	night.

247 Anthropometrics, blood pressure, fasting lipids and C-reactive protein (CRP)

248	As demonstrated in Table 2, both Liraglutide alone and in combination with CPAP
249	led to significant weight loss of $6\pm3\%$ and $4\pm4\%$, respectively, and this was accompanied by
250	an improvement in fasting triglyceride levels. In contrast, subjects on CPAP alone showed an
251	increase in body weight although this did not reach statistical significance ($2\pm5\%$, p=0.092).
252	No change in 24-hour ABPM was seen in either the CPAP or the combination group,
253	but systolic blood pressure improved in the Liraglutide group (122 \pm 8 vs 116 \pm 8 mmHg, p =
254	0.031). At baseline, there were 8 non-dippers in the Liraglutide group, 7 in the CPAP group
255	and 5 in the combination group. There was no significant change in non-dipping status in
256	any treatment group at 24 weeks (Table 2).
257	CRP levels improved the most in the CPAP group but there were no statistical
258	differences between groups (Table 2).
259	OSA parameters
260	Polysomnographic respiratory variables at baseline and at follow-up are presented in
260 261	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA.
260 261 262	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI,
260 261 262 263	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42±16/hr.
260 261 262 263 264	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42±16/hr. <u>Endothelial Function</u>
 260 261 262 263 264 265 	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42±16/hr. <u>Endothelial Function</u> A RHI via the EndoPAT device of <1.69, indicative of endothelial dysfunction, was
260 261 262 263 264 265 266	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42±16/hr. <u>Endothelial Function</u> A RHI via the EndoPAT device of <1.69, indicative of endothelial dysfunction, was present in 2 patients in the Lir group, in 7 patients in the CPAP group and in 2 patients in the
 260 261 262 263 264 265 266 267 	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42±16/hr. <u>Endothelial Function</u> A RHI via the EndoPAT device of <1.69, indicative of endothelial dysfunction, was present in 2 patients in the Lir group, in 7 patients in the CPAP group and in 2 patients in the combination group at baseline (p = 0.036). There was a negative correlation between RHI
 260 261 262 263 264 265 266 267 268 	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42 ± 16 /hr. <u>Endothelial Function</u> A RHI via the EndoPAT device of <1.69, indicative of endothelial dysfunction, was present in 2 patients in the Lir group, in 7 patients in the CPAP group and in 2 patients in the combination group at baseline (p = 0.036). There was a negative correlation between RHI and overnight baseline oxygen saturation (SpO ₂) (r = -0.527, p = 0.003) and night-time
 260 261 262 263 264 265 266 267 268 269 	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42 ± 16 /hr. <u>Endothelial Function</u> A RHI via the EndoPAT device of <1.69, indicative of endothelial dysfunction, was present in 2 patients in the Lir group, in 7 patients in the CPAP group and in 2 patients in the combination group at baseline (p = 0.036). There was a negative correlation between RHI and overnight baseline oxygen saturation (SpO ₂) (r = -0.527, p = 0.003) and night-time systolic blood pressure (r= -0.360, p = 0.05), but there was no other correlation with OSA
 260 261 262 263 264 265 266 267 268 269 270 	Polysomnographic respiratory variables at baseline and at follow-up are presented in Table 3. As expected, CPAP alone or in combination resulted in effective treatment of OSA. Liraglutide-mediated weight loss was also accompanied by significant improvement in AHI, but the effect was significantly inferior to CPAP, and the AHI remained high at 42 ± 16 /hr. <u>Endothelial Function</u> A RHI via the EndoPAT device of <1.69, indicative of endothelial dysfunction, was present in 2 patients in the Lir group, in 7 patients in the CPAP group and in 2 patients in the combination group at baseline (p = 0.036). There was a negative correlation between RHI and overnight baseline oxygen saturation (SpO ₂) (r = -0.527, p = 0.003) and night-time systolic blood pressure (r= -0.360, p = 0.05), but there was no other correlation with OSA variables. Following the treatment protocol, there was a significant improvement in RHI in

272 Changes in vascular inflammation evaluated by 18F-FDG PET-CT

273 Vascular inflammation of the aortic wall measured via PET-CT correlated with the 274 degree of baseline endothelial dysfunction as well as with baseline CRP (Supplementary 275 Table S3). In addition, there was a significant relationship between vascular inflammation 276 and both the magnitude of systolic blood pressure nocturnal dip and nocturnal systolic blood 277 pressure. Furthermore, vascular inflammation correlated significantly with the severity of 278 nocturnal hypoxia as measured via basal oxygen saturation (SpO₂) (r = -0.499, p = 0.005). 279 There was also a trend towards significant correlation between vascular inflammation and 280 baseline AHI (r=0.342, p=0.064) (Supplementary Table S3). 281 To elucidate the potential confounding effects of statin treatment on vascular 282 inflammation, we repeated the correlation analysis excluding subjects on statin treatment. 283 Correlations between baseline vascular inflammation and AHI and markers related to the 284 severity of intermittent hypoxia became stronger (Supplementary Table S3) and remained 285 significant after controlling for BMI (AHI: r = 0.482, p = 0.031, oxygen desaturation index 286 [ODI]: r = 0.497 p = 0.026, time spent with SpO₂<90% of total sleep time [TST90]: r =0.471, p = 0.036). 287 288 Investigating the change in vascular inflammation over 24 weeks, there was a 289 significant reduction in the CPAP group (change in aortic wall TBR from 2.03±0.34 to 290 1.84 ± 0.43 , p 0.010; representative example shown in Figure 1), which was significant when 291 compared to the Liraglutide group (p = 0.028) with a similar trend towards a reduction in 292 inflammation in the combination group. Liraglutide-mediated weight loss alone, however, did

293 not result in a significant change (Figure 2A). The change in vascular inflammation showed a

significant negative correlation with change in basal SpO₂ (r=-0.412, p=0.026) and a close to

significant correlation with change in AHI (r=0.337, p=0.074). Again, when patients on

stating were excluded, the changes in vascular inflammation in the CPAP and combination

- 297 groups were enhanced (Figure 2B).
- 298 Changes in coronary artery plaque volumes
- 299 Visual analysis of baseline CCTA revealed CAD in 17/30 (47%) subjects, of whom 2 300 had been previously diagnosed. The CAC score in those patients was 65+/-194 with no 301 difference between treatment groups at baseline. Of the 17 subjects with visually identifiable 302 CAD, 11 had single-vessel disease (5 Lir, 3 CPAP, 3 combination), 4 had two-vessel disease 303 (1 Lir, 1 CPAP, 2 combination, and 2 had three-vessel disease (1 CPAP, 1 combination). 304 Quantitative assessment of calcified plaque (CP) volume correlated closely with the visually 305 obtained CAC score (r = 0.767, p < 0.001), but there was no relationship between non-306 calcified (NCP) or low-attenuation (LD NCP) volume with this measure. 307 At baseline, all plaque subtype volumes were similar between groups. There was a 308 trend towards significant correlation between LD NCP volume and baseline fasting 309 triglyceride levels (r=0.366, p=0.051), and this relationship remained similar following 310 adjustment for BMI (r= 0.365, p = 0.056). There were no significant correlations between 311 plaque measures and OSA parameters in the whole cohort, but TST90 correlated with CP 312 volume in the group who did not take statin medication (r = 0.607, p 0.005). 313 The 17 subjects with visible coronary artery plaque on the baseline scan underwent 314 repeat CCTA after 24 weeks, and those were evenly distributed between groups (6 Lir, 6 315 CPAP, 5 combination). Although limited given the small group, there was a reduction in LD 316 NCP volume with CPAP (619 ± 532 vs 364 ± 190 mm³) and with combination therapy 317 $(401\pm145 \text{ vs } 278\pm126 \text{ mm}^3)$, and there was no change with Liraglutide alone (545±335 vs 318 503±229 mm³) (Figure 3). Changes in total and NCP volume followed similar patterns but 319 there were no relevant changes in CP burden with any treatment. Representative images from 320 a study participant of the CPAP alone arm are presented in Figure 4.

321	Evaluating the total group of subjects undergoing repeat CCTA, there was a
322	significant univariate correlation between the reduction in NCP volume and the reduction in
323	TST90 ($r = 0.505$, $p = 0.038$), and a trend towards significant correlation with the reduction
324	in AHI and ODI ($r = 0.457$, $p = 0.065$ and $r = 0.463$, $p = 0.061$, respectively) (Figure 5).
325	Furthermore, there was a trend towards significant correlations between the reduction in
326	vascular inflammation and reduction in both NCP and LD NCP volume ($r = 0.447$, $p = 0.072$
327	and $r = 0.436$, $p = 0.080$, respectively). Finally, improvement in endothelial function as
328	measured by the RHI showed a close to statistically significant correlation with reduction in
329	total plaque volume, but not with either NCP or LD NCP volume ($r = -0.475$, $p = 0.063$).

330 Discussion

331 In this report we demonstrate that CPAP therapy but not a GLP-1-mediated weight 332 loss regimen improves early and potentially modifiable atherosclerotic processes in OSA. As 333 this was a proof-of-concept study with only a small number of participants the statistical 334 differences in improvement in vascular inflammation between the treatment arms are 335 particularly striking and support the benefit of CPAP in the primary prevention of CV disease 336 processes in OSA. The role of CPAP therapy in the treatment of CV diseases and particularly 337 in the prevention of CV events in subjects with OSA has been subject of major controversy. 338 Three randomized controlled trials failed to demonstrate attenuation in the incidence of CV events in cohorts with established CV diseases⁴⁻⁶. However, exclusion of patients with severe 339 340 daytime sleepiness and low adherence to CPAP therapy were substantial limitations and in 341 contrast, analyses from large real-world studies revealed a significant association of CPAP use with lower all-cause mortality²⁸⁻³⁰. Furthermore, several studies and meta-analyses have 342 343 demonstrated a clinically meaningful improvement with CPAP of various cardiovascular risk factors including blood pressure or endothelial function^{8,9}. Importantly, the presence of OSA 344 appears to be particularly detrimental in subjects without prior CV disease³¹. This ties in with 345

346	an extensive line of evidence showing that intermittent hypoxia, the hallmark feature of
347	obstructive sleep apnea and key pathophysiological factor in CV disease processes in OSA, is
348	a potent triggering factor of inflammatory processes which are also characteristic of early
349	stages of atherosclerosis ^{32,33} . We and others have previously shown that OSA subjects
350	without CV disease exhibit a low-grade systemic pro-inflammatory milieu which is
351	attenuated by effective CPAP therapy ^{11,34} . The CPAP effect on aortic inflammation as
352	evaluated by FDG PET-CT, on LD NCP coronary artery plaque burden and on endothelial
353	function found in our present report_support these findings and highlight the potential
354	opportunity for early intervention to mitigate CV risk in OSA. Notably, compliance with
355	CPAP was excellent in our cohort and adequate adherence commonly referred to as usage of
356	4 or more hours per night has emerged as being critical to achieve CV benefit ³⁵ . Our small
357	numbers do not allow further insight into the dose-effect relationship between CPAP and CV
358	processes, but this topic will remain a research priority.
359	Although adherence and tolerability with Liraglutide were also satisfactory and
360	significant weight loss was achieved accompanied by improvement in triglyceride levels and
361	blood pressure, this did not translate into improvement of early atherosclerotic disease in our
362	study. The general health benefits of weight loss are unquestionable and have also been
363	demonstrated in OSA populations ³⁶⁻³⁸ . However, most studies have focused on improvement
364	in OSA parameters or metabolic outcomes. In a landmark study, Chirinos and co-workers
365	reported improvement in various parameters with weight loss including insulin sensitivity
366	and blood pressure in obese subjects with obesity and moderate to severe OSA in contrast to
367	CPAP therapy. Of note, there appeared to be an incremental benefit with both treatments
368	combined ¹⁷ . However, that study employed intensive weight loss coaching and dietary
369	restriction that are not feasible in real world populations. GLP-1 in combination with lifestyle
370	change is superior in achieving weight loss, compared to lifestyle change alone, and is now

371	widely used as an obesity treatment ³⁹ . The SCALE sleep apnea trial evaluated this
372	pharmacological intervention versus placebo over 32 weeks in moderate to severe OSA
373	subjects who were unwilling or unable to use CPAP and reported a small but statistically
374	significant improvement in AHI, systolic blood_pressure and HbA1c ⁴⁰ . Our study is the first
375	to compare the impact of GLP-1 induced weight loss with CPAP therapy (alone or in
376	combination) and also the first to address the potential impact on early CV disease processes.
377	Weight loss achieved in the Liraglutide group was comparable to that seen in the SCALE
378	sleep apnea trial but was less in the combination group. This was likely due to difficulties for
379	some subjects in managing both treatments concomitantly, also reflected in the lower CPAP
380	compliance in comparison to those on CPAP alone. We used a very pragmatic, easily
381	applicable approach for standard clinical populations. We did not provide specific dietary or
382	exercise advice to patients in the CPAP group reflecting our standard practice. However, as a
383	consequence we cannot rule out a potential added benefit on CV disease with combined
384	CPAP and Liraglutide. Furthermore, continuous weight loss beyond our 24-week timepoint
385	might potentially relate into more noticeable improvements but this remains hypothetical at
386	this stage. Nonetheless, our data support a direct contribution of OSA to the process of
387	atherosclerosis and the significant correlations of oximetry parameters with our CV outcomes
388	reinforces the pivotal role of intermittent hypoxia as triggering factor. The relationship
389	between OSA and CV disease was particularly strong in subjects not on statin therapy. Statin
390	medication is the cornerstone therapy to attenuate CV disease progression and their effects
391	are not solely mediated by their lipid-lowering properties but also through pleiotropic effects
392	reducing vascular inflammation and promoting atherosclerotic plaque stability ^{41,42} . Statin use
393	among OSA patients has been consistently reported to be low ^{43,44} and studies assessing the
394	benefits of statins in OSA populations have been conflicting. In a French multicenter double-
395	blind RCT endothelial function remained unaffected although statins improved blood

pressure and lipid profile⁴⁵. In contrast, a recent report demonstrated reduction of
complement-mediated pro-inflammatory effects with restoration of endothelial protection⁴⁶.
Our study was not designed to assess this aspect but supports the need for further research
into the role of statins in OSA-mediated CV disease either in combination with CPAP or as
primary preventive strategy alone.

401 A particular strength of our study is the evaluation of early and potentially reversible 402 atherosclerotic disease using state-of-the art imaging techniques. This is the first time that 403 18F-FDG PET-CT has been used in an OSA population. Vascular inflammation on 18F-FDG 404 PET-CT has been shown to predict the formation of future atherosclerotic plaques and moreover, to correlate with subsequent vascular events^{13,47}. Importantly, the reduction in 405 406 aortic inflammation by CPAP therapy in our study is at least of the magnitude seen with statin therapy⁴⁸ and thus, is likely of clinical relevance. In contrast to PET-CT assessment of 407 408 atherosclerosis, CCTA is well established in routine clinical practice and increased calcified 409 coronary artery plaque burden on CT calcium scoring is predicative of future coronary events^{49,50}. We reported previously an increased plaque burden in otherwise healthy OSA 410 subjects versus matched controls⁵¹ and data from the Multi-Ethnic Study of Atherosclerosis 411 412 (MESA) cohort demonstrated an independent association between OSA severity and progression of calcified coronary artery plaques over an 8-year period⁵². However, calcified 413 414 plaques represent a more stable form of atherosclerosis less likely to rupture and cause 415 myocardial infarction. Histologically, a lipid-rich necrotic core is an important characteristic 416 associated with plaque rupture⁵³ and those can be accurately identified on CCTA as low-417 attenuation noncalcified plaque and accurately quantified through semi-automatic analysis. 418 Accordingly, low-attenuation plaque has been demonstrated to be a better predictor of 419 myocardial infarction than other traditionally used markers including coronary artery stenosis⁵⁴. In a large cross-sectional study of 692 subjects, OSA severity correlated strongly 420

421	with CP and NCP burden and subjects with moderate to severe OSA were more likely to
422	contain a LD NCP component than controls ⁵⁵ . Unfortunately, we were not able to repeat
423	CCTA's in all our subjects following their interventions due to the ethical restrictions
424	regarding radiation exposure but nonetheless with our small numbers, there was a noticeable
425	trend in reduction with CPAP in LD NCP volume only, supporting the potential importance
426	of effective OSA treatment on the early pro-inflammatory phase of atherosclerosis.
427	These data have been derived from a proof-of concept study and thus, have inherent
428	limitations including low numbers, an open-label design and a focus on a selected, well-
429	characterized population. In addition, in line with other RCT's in the field, we excluded
430	subjects with severe daytime sleepiness who may benefit most from CPAP.
431	Despite these limitations, our data provide sufficient evidence to mandate the design
432	and delivery of larger-scale studies to define the role of CPAP in attenuating CV risk as
433	primary prevention in subjects with OSA. There is also a clear need to integrate novel
434	radiological surrogate markers of cardiovascular disease with clinical endpoints.

435 Acknowledgement

We are grateful to all the patients and their families for participating in this study and to all staff members of the Sleep Laboratory at St. Vincent's University Hospital for their help and support.

439 Sources of Funding

This study was funded by the Health Research Board of Ireland (SR). Further support
was provided by an unrestricted grant from Novo Nordisk, Ireland but the company had no
influence in the design, the running, and the analysis of the study. The not-for-profit
Heartbeat Trust CLG (<u>www.heartbeattrust.ie</u>) founded by KMcD and ML provided the Circle
CVI software.

445 **Disclosures**

446	CO'D, SC, AO'M, BO'R, MT, RG, DO'S and DM have nothing to disclose. KMcD
447	has received grants from Interreg North West Europe and has acted as speaker and consultant
448	for Boehringer Ingelheim, Astra Zeneca, FIRE -1 and Vifor Pharmaceuticals. ML has board
449	membership and shares in Solvotrin Therapeutics, is a named inventor on several patents
450	relating to anti-inflammatory effects of isosorbide prodrugs and novel formulations of iron
451	and in receipt of grant funding from Novartis, Genuity Science, the Irish Research Council
452	and ESTHER Ireland. JDD has received grant support from the Irish Lung Foundation, the
453	St. Vincent's Hospital Group Foundation, University College Dublin and the FP7 Program of
454	the European Commission for the randomized multicenter DISCHARGE trial (603266-2,
455	HEALTH-2012.2.42); is an Associate Editor of Radiology and the Quarterly Journal of
456	Medicine; is an Editorial Board member of Radiology Cardiothoracic Imaging; is an author
457	in the Stat-Dx book Series Diagnostic Imaging – Cardiovascular and the textbook CT and
458	MRI in Cardiology, Elsevier and has received speaker fees from Boehringer Ingelheim. SR
459	received unrestricted grants from Novo Nordisk and Fitbit.

460 Supplementary Material

- 461 Supplemental Methods
- 462 Tables S1-S3
- 463 Figure S1-S2

464 **<u>References</u>**

466	1.	Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez
467		CM, Patel SR, Penzel T, Pépin J-L, et al. Estimation of the global prevalence and
468		burden of obstructive sleep apnoea: a literature-based analysis. The Lancet
469		Respiratory Medicine. 2019;7:687-698. doi: 10.1016/S2213-2600(19)30198-5
470	2.	O'Donnell C, O'Mahony AM, McNicholas WT, Ryan S, Cardiovascular
471		manifestations in obstructive sleep apnea: current evidence and potential mechanisms.
472		Pol Arch Intern Med. 2021:131:550-560. doi: 10.20452/pamw.16041
473	3.	Javaheri S. Barbe F. Campos-Rodriguez F. Dempsey JA, Khavat R. Javaheri S.
474	-	Malhotra A. Martinez-Garcia MA. Mehra R. Pack AI. et al. Sleep Appea: Types.
475		Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol.
476		2017:69:841-858. doi: 10.1016/i.jacc.2016.11.069
477	4.	McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R,
478		Drager LF, Liu Z, et al. CPAP for Prevention of Cardiovascular Events in Obstructive
479		Sleep Appea. N Engl J Med. 2016:375:919-931. doi: 10.1056/NEJMoa1606599
480	5.	Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunstrom E. Effect of
481		Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease
482		Patients with Nonsleepv Obstructive Sleep Apnea. The RICCADSA Randomized
483		Controlled Trial. Am J Respir Crit Care Med. 2016;194:613-620. doi:
484		10.1164/rccm.201601-0088OC
485	6.	Sanchez-de-la-Torre M, Sanchez-de-la-Torre A, Bertran S, Abad J, Duran-Cantolla J,
486		Cabriada V, Mediano O, Masdeu MJ, Alonso ML, Masa JF, et al. Effect of
487		obstructive sleep apnoea and its treatment with continuous positive airway pressure
488		on the prevalence of cardiovascular events in patients with acute coronary syndrome
489		(ISAACC study): a randomised controlled trial. Lancet Respir Med. 2020;8:359-367.
490		doi: 10.1016/S2213-2600(19)30271-1
491	7.	Pengo MF, Soranna D, Giontella A, Perger E, Mattaliano P, Schwarz EI, Lombardi C,
492		Bilo G, Zambon A, Steier J, et al. Obstructive sleep apnoea treatment and blood
493		pressure: which phenotypes predict a response? A systematic review and meta-
494		analysis. Eur Respir J. 2020;55. doi: 10.1183/13993003.01945-2019
495	8.	Shang W, Zhang Y, Liu L, Chen F, Wang G, Han D. Benefits of continuous positive
496		airway pressure on blood pressure in patients with hypertension and obstructive sleep
497		apnea: a meta-analysis. Hypertens Res. 2022;45:1802-1813. doi: 10.1038/s41440-
498		022-00954-9
499	9.	Schwarz EI, Puhan MA, Schlatzer C, Stradling JR, Kohler M. Effect of CPAP therapy
500		on endothelial function in obstructive sleep apnoea: A systematic review and meta-
501		analysis. Respirology (Carlton, Vic). 2015;20:889-895. doi: 10.1111/resp.12573
502	10.	Chalegre ST, Lins-Filho OL, Lustosa TC, Franca MV, Couto TLG, Drager LF,
503		Lorenzi-Filho G, Bittencourt MS, Pedrosa RP. Impact of CPAP on arterial stiffness in
504		patients with obstructive sleep apnea: a meta-analysis of randomized trials. Sleep
505		Breath. 2021;25:1195-1202. doi: 10.1007/s11325-020-02226-7
506	11.	Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-kappaB-
507		dependent genes in obstructive sleep apnea syndrome. American Journal of
508		Respiratory and Critical Care Medicine. 2006;174:824-830. doi:
509		10.1164/rccm.200601-066OC
510	12.	Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the
511		pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?
512		<i>Thorax.</i> 2009;64:631-636. doi: 10.1136/thx.2008.105577

513 514 515 516 517	13.	Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, Nikolaou K, Reiser MF, Bartenstein P, Hacker M. 18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease. <i>Journal of Nuclear Medicine</i> . 2009;50:1611-1620. doi: 10.2967/jnumed.109.065151
518 519 520 521 522	14.	Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>
523 524	15	2021;144:e368-e454. doi: 10.1161/CIR.000000000001029 Shaw LJ, Blankstein R, Bax JJ, Ferencik M, Bittencourt MS, Min JK, Berman DS
525 526 527 528		Leipsic J, Villines TC, Dey D, et al. Society of Cardiovascular Computed Tomography / North American Society of Cardiovascular Imaging - Expert Consensus Document on Coronary CT Imaging of Atherosclerotic Plaque. J Cardiovasc Comput Tomogr. 2021;15:93-109. doi: 10.1016/j.jcct.2020.11.002
529 530 531 532	16.	Williams MC, Kwiecinski J, Doris M, McElhinney P, D'Souza MS, Cadet S, Adamson PD, Moss AJ, Alam S, Hunter A, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results From the Multicenter SCOT-HEART Trial (Scottish Computed
532 533 534		Tomography of the HEART). <i>Circulation</i> . 2020;141:1452-1462. doi: 10.1161/CIRCULATIONAHA.119.044720
535 536 537	17.	Chirinos JA, Gurubhagavatula I, Teff K, Rader DJ, Wadden TA, Townsend R, Foster GD, Maislin G, Saif H, Broderick P, et al. CPAP, weight loss, or both for obstructive sleep appea. <i>N Engl I Med</i> . 2014:370:2265-2275. doi: 10.1056/NEIMoa1306187
538 539	18.	The Food Pyramid. Department of Health. https://www.hse.ie/eng/about/who/healthwellbeing/our-priority-
540 541 542	19.	programmes/heal/heal-docs/food%20pyramid%20professional%20version.pdf. 2016. Keeping active. Healthy Ireland. <u>https://www.gov.ie/en/publication/16d3c-keeping-</u>
542 543 544 545	20.	Berry RB, Quan SF, Abreu AR, Bibbs ML, DelRosso L, Harding SM, Mao M-M, Plante DD, Pressman MR, Troester MM, et al. <i>The AASM Manual for the Scoring of</i> <i>Sleep and Associated Events: Rules Terminology and Technical Specifications</i>
546 547	21.	Darien, IL: American Academy of Sleep Medicine; 2020. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Jr., Kuvin JT, Lerman A.
548 549 550		Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. <i>J Am Coll Cardiol</i> . 2004;44:2137-2141. doi: 10.1016/j.jacc.2004.08.062
551 552	22.	Axtell AL, Gomari FA, Cooke JP. Assessing Endothelial Vasodilator Function with the Endo-PAT 2000. <i>J Vis Exp.</i> 2010:2167. doi: 10.3791/2167
553 554 555 556 557	23.	Bucerius J, Hyafil F, Verberne HJ, Slart RH, Lindner O, Sciagra R, Agostini D, Ubleis C, Gimelli A, Hacker M, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. <i>Eur J Nucl Med Mol Imaging</i> . 2016;43:780-792. doi: 10.1007/s00259-015-3259-3
558 559 560 561 562	24.	Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, Teague HL, Harrington CL, Rivers JP, Chung JH, et al. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography. <i>JAMA Cardiol</i> . 2017;2:1013-1018. doi: 10.1001/jamacardio.2017.1213

563	25.	Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, Ng Q, Joshi
564		AA, Krishnamoorthy P, Dave J, et al. Severity of Psoriasis Associates With Aortic
565		Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a
566		Prospective Observational Study. Arterioscler Thromb Vasc Biol. 2015;35:2667-
567		2676. doi: 10.1161/ATVBAHA.115.306460
568	26.	Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R.
569		Quantification of coronary artery calcium using ultrafast computed tomography. JAm
570		Coll Cardiol. 1990;15:827-832. doi: 10.1016/0735-1097(90)90282-t
571	27.	Dey D, Schepis T, Marwan M, Slomka PJ, Berman DS, Achenbach S. Automated
572		three-dimensional quantification of noncalcified coronary plaque from coronary CT
573		angiography: comparison with intravascular US. Radiology. 2010;257:516-522. doi:
574		10.1148/radiol.10100681
575	28.	de Batlle J, Bertran S, Turino C, Escarrabill J, Dalmases M, Garcia-Altes A, Sapina-
576		Beltran E, Carbonell EM, Sanchez-de-la-Torre M, Barbe F. Longitudinal Analysis of
577		Causes of Mortality in Continuous Positive Airway Pressure-treated Patients at the
578		Population Level. Ann Am Thorac Soc. 2021;18:1390-1396. doi:
579		10.1513/AnnalsATS.202007-888OC
580	29.	Nakamura K, Nakamura H, Tohyama K, Takara C, Iseki C, Woodward M, Iseki K.
581		Survival benefit of continuous positive airway pressure in Japanese patients with
582		obstructive sleep apnea: a propensity-score matching analysis. J Clin Sleep Med.
583		2021;17:211-218. doi: 10.5664/jcsm.8842
584	30.	Pepin JL, Bailly S, Rinder P, Adler D, Benjafield AV, Lavergne F, Josseran A, Sinel-
585		Boucher P, Tamisier R, Cistulli PA, et al. Relationship Between CPAP Termination
586		and All-Cause Mortality: A French Nationwide Database Analysis. Chest.
587		2022;161:1657-1665. doi: 10.1016/j.chest.2022.02.013
588	31.	Zapater A, Sanchez-de-la-Torre M, Benitez ID, Targa A, Bertran S, Torres G,
589		Aldoma A, De Batlle J, Abad J, Duran-Cantolla J, et al. The Effect of Sleep Apnea on
590		Cardiovascular Events in Different Acute Coronary Syndrome Phenotypes. Am J
591		Respir Crit Care Med. 2020;202:1698-1706. doi: 10.1164/rccm.202004-1127OC
592	32.	Ryan S, Cummins EP, Farre R, Gileles-Hillel A, Jun JC, Oster H, Pepin JL, Ray DW,
593		Reutrakul S, Sanchez-de-la-Torre M, et al. Understanding the pathophysiological
594		mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards
595		personalised treatment approaches. Eur Respir J. 2020;56. doi:
596		10.1183/13993003.02295-2019
597	33.	Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways
598		by intermittent hypoxia in obstructive sleep apnea syndrome. <i>Circulation</i> .
599	2.4	2005;112:2660-2667. doi: 10.1161/CIRCULATIONAHA.105.556746
600	34.	Ryan S, McNicholas W I. Inflammatory cardiovascular risk markers in obstructive
601		sleep apnoea syndrome. Cardiovascular & Hematological Agents in Medicinal
602	25	Chemistry. 2009 ; /: /6-81. doi: 10.21/4/18/152509/8/04/685
603	35.	Pack AI, Magalang UJ, Singh B, Kuna SI, Keenan BI, Maislin G. Randomized
604		clinical trials of cardiovascular disease in obstructive sleep apnea: understanding and
605	26	overcoming bias. Sleep. 2021;44. doi: 10.1093/sleep/zsaa229
606	36.	Carneiro-Barrera A, Amaro-Ganete FJ, Guillen-Riqueime A, Jurado-Fasoli L, Saez-
607		Roca G, Martin-Carrasco C, Buela-Casal G, Ruiz JR. Effect of an Interdisciplinary
008		weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The
009 610		IN I EKAPINEA Kandomized Clinical Irial. JAMA Netw Open. 2022;5:e228212. doi: 10.1001/jamanatwarkanan.2022.9212
010 611	27	10.1001/jamanetworkopen.2022.8212 Edwards DA Dristow C O'Driscoll DM Works AM Chari L Devidson 7E Verse
612	57.	Luwalus DA, DIIStow C, O DIIScoll Divi, wolig Aivi, Glazi L, Davidson ZE, Young
012		A, muoy n, names 1r, nammon 05. Assessing the impact of diet, exercise and the

(10		
613		combination of the two as a treatment for OSA: A systematic review and meta-
614		analysis. <i>Respirology (Carlton, Vic)</i> . 2019;24:740-751. doi: 10.1111/resp.13580
615	38.	Georgoulis M, Yiannakouris N, Kechribari I, Lamprou K, Perraki E, Vagiakis E,
616		Kontogianni MD. Sustained improvements in the cardiometabolic profile of patients
617		with obstructive sleep apnea after a weight-loss Mediterranean diet/lifestyle
618		intervention: 12-month follow-up (6 months post-intervention) of the "MIMOSA"
619		randomized clinical trial. Nutr Metab Cardiovasc Dis. 2023. doi:
620		10 1016/i numecd 2023 02 010
621	39	Pi-Sunver X, Astrup A, Fujjoka K, Greenway F, Halpern A, Krempf M, Lau DC, le
622	57.	Roux CW Violante Ortiz R Jensen CB et al A Randomized Controlled Trial of 3.0
623		mg of Liraglutide in Weight Management N Engl I Med 2015:373:11-22 doi:
624		10 1056/NFIM ₀₂ 1411802
625	40	Plackman & Foster GD Zammit G Dosenherg P Aronne I Wadden T Claudius P
626	40.	Jackman A, Foster OD, Zammit O, Kosenberg K, Afonne L, Wadden T, Claudius D, Jansen CD. Mignet E. Effect of linesbuilde 2.0 mg in individuals with obesity and
020		Jensen CB, Mignoi E. Effect of firagiluide 5.0 mg in individuals with obesity and
627		moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized
628	4.1	clinical trial. Int J Obes (Lond). $2016;40:1310-1319$. doi: $10.1038/ij0.2016.52$
629	41.	Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ,
630		Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 ACC/AHA
631		Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the
632		American College of Cardiology/American Heart Association Task Force on Clinical
633		Practice Guidelines. <i>Circulation</i> . 2019;140:e596-e646. doi:
634		10.1161/CIR.000000000000678
635	42.	Razavi AC, Mehta A, Sperling LS. Statin therapy for the primary prevention of
636		cardiovascular disease: Pros. Atherosclerosis. 2022;356:41-45. doi:
637		10.1016/j.atherosclerosis.2022.07.004
638	12	Cattlich DI Vanalman C Neuman AD OlCannan CT Durich: NM Oyan SE
050	45.	Gouned DJ, Yenokyan G, Newman AB, O Connor GT, Punjabi NM, Quan SF,
639	43.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of
639 640	43.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep
639 640 641	43.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i> . 2010;122:352-360. doi:
639 640 641 642	-3.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i> . 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801
639 640 641 642 643	44.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i> . 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva
638 639 640 641 642 643 644	44.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i> . 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration,
638 639 640 641 642 643 644 645	44.	Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i> . 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil
638 639 640 641 642 643 644 645 646	44.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjaoi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi:
638 639 640 641 642 643 644 645 646 647	44.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644
639 640 641 642 643 644 645 646 647 648	43. 44. 45.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G,
639 640 641 642 643 644 645 646 647 648 649	43.44.45.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin
638 639 640 641 642 643 644 645 646 647 648 649 650	43.44.45.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled
639 640 641 642 643 644 645 646 647 648 649 650 651	43.44.45.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014;423120. doi: 10.1155/2014/423120
639 640 641 642 643 644 645 646 647 648 649 650 651 652	43.44.45.46.	 Gottheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S.
639 640 641 642 643 644 645 646 647 648 649 650 651 652 653	43.44.45.46.	 Gottheb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive
639 640 641 642 643 644 645 646 647 648 647 648 649 650 651 652 653 654	43.44.45.46.	 Gottheb DJ, Yehokyan G, Newman AB, O'Connor G1, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654	43.44.45.46.	 Gottheo DJ, Yehokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-761OC
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656	 43. 44. 45. 46. 47. 	 Goutheo DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-761OC Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657	 43. 44. 45. 46. 47. 	 Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation.</i> 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol.</i> 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm.</i> 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc.</i> 2023. doi: 10.1513/AnnalsATS.202209-761OC Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TL Hoffmann U Tawakol A, Focal arterial inflammation precedes subsequent
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658	43.44.45.46.47.	 Redline DJ, Yenokyan G, Newman AB, O'Connor GT, Punjaoi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-761OC Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. <i>Circ</i>
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659	 44. 45. 46. 47. 	 Boutheb DJ, Yehokyan G, Newman AB, O'Connor GT, Punjaoi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-7610C Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calification in the same location: a longitudinal FDG-PET/CT study. <i>Circ</i> <i>Cardiovasc Imaging</i>. 2013;6:747-754. doi: 10.1161/CIRCIMAGING 113.000382
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660	 43. 44. 45. 46. 47. 48 	 Bottheb DJ, Yehokyah G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-761OC Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calification in the same location: a longitudinal FDG-PET/CT study. <i>Circ</i> <i>Cardiovasc Imaging</i>. 2013;6:747-754. doi: 10.1161/CIRCIMAGING.113.000382 Tawakol A, Fayad ZA, Moog B, Alon A, Klimas MT, Dansky H, Subramanian SS
638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661	 43. 44. 45. 46. 47. 48. 	 Botheo DJ, Yehokyan G, Newman AB, O'Connor GT, Punjaoi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-7610C Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calification in the same location: a longitudinal FDG-PET/CT study. <i>Circ</i> <i>Cardiovasc Imaging</i>. 2013;6:747-754. doi: 10.1161/CIRCIMAGING.113.000382 Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, Abdelbaky A, Rudd IHE Farkoub ME et al. Intensification of Statin Therarpy Resulte
$\begin{array}{c} 638\\ 639\\ 640\\ 641\\ 642\\ 643\\ 644\\ 645\\ 644\\ 645\\ 646\\ 647\\ 648\\ 649\\ 650\\ 651\\ 652\\ 653\\ 654\\ 655\\ 656\\ 657\\ 658\\ 659\\ 660\\ 661\\ 662\\ \end{array}$	 43. 44. 45. 46. 47. 48. 	 Botheo DJ, Yehokyan G, Newman AB, O'Connor GT, Punjaoi NM, Quan SF, Redline S, Resnick HE, Tong EK, Diener-West M, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. <i>Circulation</i>. 2010;122:352-360. doi: 10.1161/CIRCULATIONAHA.109.901801 Souza SP, Santos RB, Santos IS, Parise BK, Giatti S, Aielo AN, Cunha LF, Silva WA, Bortolotto LA, Lorenzi-Filho G, et al. Obstructive Sleep Apnea, Sleep Duration, and Associated Mediators With Carotid Intima-Media Thickness: The ELSA-Brasil Study. <i>Arterioscler Thromb Vasc Biol</i>. 2021;41:1549-1557. doi: 10.1161/ATVBAHA.120.315644 Joyeux-Faure M, Tamisier R, Baguet JP, Dias-Domingos S, Perrig S, Leftheriotis G, Janssens JP, Trzepizur W, Launois SH, Stanke-Labesque F, et al. Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial. <i>Mediators Inflamm</i>. 2014;2014:423120. doi: 10.1155/2014/423120 Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, Garfinkel J, Wei Y, Jelic S. Statins Restore Endothelial Protection against Complement Activity in Obstructive Sleep Apnea: A Randomized Trial. <i>Ann Am Thorac Soc</i>. 2023. doi: 10.1513/AnnalsATS.202209-761OC Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, Brady TJ, Hoffmann U, Tawakol A. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. <i>Circ</i> <i>Cardiovasc Imaging</i>. 2013;6:747-754. doi: 10.1161/CIRCIMAGING.113.000382 Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, Abdelbaky A, Rudd JHF, Farkouh ME, et al. Intensification of Statin Therapy Results

663		Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography
664		Feasibility Study. J Am Coll Cardiol. 2013;62:909-917. doi:
665		10.1016/j.jacc.2013.04.066
666	49.	Choi EK, Choi SI, Rivera JJ, Nasir K, Chang SA, Chun EJ, Kim HK, Choi DJ,
667		Blumenthal RS, Chang HJ. Coronary computed tomography angiography as a
668		screening tool for the detection of occult coronary artery disease in asymptomatic
669		individuals. J Am Coll Cardiol. 2008;52:357-365. doi: 10.1016/j.jacc.2008.02.086
670	50.	O'Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM,
671		Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL, Jr., et al.
672		American College of Cardiology/American Heart Association Expert Consensus
673		document on electron-beam computed tomography for the diagnosis and prognosis of
674		coronary artery disease. Circulation. 2000;102:126-140. doi:
675		10.1161/01.cir.102.1.126
676	51.	Kent BD, Garvey JF, Ryan S, Nolan G, Dodd JD, McNicholas WT. Severity of
677		obstructive sleep apnoea predicts coronary artery plaque burden: a coronary computed
678		tomographic angiography study. Eur Respir J. 2013;42:1263-1270. doi:
679		10.1183/09031936.00094812
680	52.	Kwon Y, Duprez DA, Jacobs DR, Nagayoshi M, McClelland RL, Shahar E, Budoff
681		M, Redline S, Shea S, Carr JJ, et al. Obstructive sleep apnea and progression of
682		coronary artery calcium: the multi-ethnic study of atherosclerosis study. J Am Heart
683		Assoc. 2014;3:e001241. doi: 10.1161/JAHA.114.001241
684	53.	Voros S, Rinehart S, Qian Z, Joshi P, Vazquez G, Fischer C, Belur P, Hulten E,
685		Villines TC. Coronary atherosclerosis imaging by coronary CT angiography: current
686		status, correlation with intravascular interrogation and meta-analysis. JACC
687		Cardiovasc Imaging. 2011;4:537-548. doi: 10.1016/j.jcmg.2011.03.006
688	54.	Williams MC, Kwiecinski J, Doris M, McElhinney P, D'Souza MS, Cadet S,
689		Adamson PD, Moss AJ, Alam S, Hunter A, et al. Low-Attenuation Noncalcified
690		Plaque on Coronary Computed Tomography Angiography Predicts Myocardial
691		Infarction. Circulation. 2020;141:1452-1462. doi:
692		10.1161/CIRCULATIONAHA.119.044720
693	55.	Lu M, Fang F, Wang Z, Xu L, Sanderson JE, Zhan X, He L, Wu C, Wei Y.
694		Association Between OSA and Quantitative Atherosclerotic Plaque Burden: A
695		Coronary CT Angiography Study. <i>Chest</i> . 2021;160:1864-1874. doi:
696		10.1016/j.chest.2021.07.040
697	56.	Matsumoto H, Watanabe S, Kyo E, Tsuji T, Ando Y, Otaki Y, Cadet S, Gransar H,
698		Berman DS, Slomka P, et al. Standardized volumetric plaque quantification and
699		characterization from coronary CT angiography: a head-to-head comparison with
700		invasive intravascular ultrasound. <i>Eur Radiol</i> . 2019;29:6129-6139. doi:
701		10.1007/s00330-019-06219-3
702		
703		

	Total	Liraglutide n=10	CPAP n=10	Combination n=10	p-value
Female	6 (20)	2 (20)	1 (10)	3 (30)	0.535
Age (years)	50±7	50±9	51±8	50±5	0.959
BMI (kg/m ²)	35.0±3.1	35.0±3.1	36.0±3.2	34.0±3.3	0.527
Epworth Sleepiness Scale	9±5	8±6	7±4	11±5	0.245
AHI	50±19	53±20	50±21	47±16	0.816
Hypertension	7 (23)	3 (30)	3 (30)	1 (10)	0.475
Ischemic Heart Disease	2 (7)	0 (0)	0 (0)	2 (20)	0.137
Statin Use	9 (30)	3 (30)	2 (20)	4 (40)	0.621
Anti-Hypertensive Medication Use	10 (33)	3 (30)	3 (30)	4 (40)	0.861
Smoking Status:					
• Current smoker	3 (10)	0 (0)	2 (20)	1 (10)	0.329
• Ex-smoker	16 (53)	4 (40)	6 (60)	6 (60)	0.585
• Never-smoker	11 (37)	6 (60)	2 (20)	3 (30)	0.155
Smoking Pack Years	22±10	20±14	21±9	24±10	0.812
24-hr mean systolic BP (mmHg)	121±12	126±13	119±10	120±12	0.359

24-hr mean diastolic BP (mmHg)	74±8	76±9	72±6	75±8	0.425
Non-dippers	20 (67)	7 (70)	8 (80)	5 (50)	0.350
HbA1c (mmol/mol)	38.4±3.2	38.4±3.9	37.8±2.6	39.0±3.1	0.784
Total Cholesterol (mmol/l)	4.80±0.99	5.35±1.17	4.68±0.66	4.36±0.90	0.071
Triglyceride (mmol/l)	1.88±0.90	2.09±0.76	1.84±1.00	1.72±0.97	0.66
HDL Cholesterol (mmol/l)	1.09±0.23	1.13±0.21	1.02±0.28	1.13±0.21	0.458
LDL Cholesterol (mmol/l)	2.85±0.82	3.28±0.89	2.83±0.48	2.45±0.86	0.07
T.Chol/HDL Ratio	4.53±1.08	4.81±1.00	4.84±1.10	3.95±0.99	0.111

704 **Table 1: Baseline Characteristics of the study population (n = 30).** (*CPAP = continuous*

705 positive airway pressure, BMI = body mass index; BP = blood pressure, AHI = apnea-

706 *hypopnea index, HDL = high-density lipoproteins, LDL = low-density lipoproteins, HbA1c*

707 = glycosylated hemoglobin. Data are expressed as mean \pm SD or n (%))

7	1	Λ
1	T	υ

	Liraglutide	СРАР	Combination
Change in Weight (kg)	-6.17±3.57*	2.30±4.57	-3.67±4.22*
Change in Waist Circumference (cm)	-4.25±6.11	0.75±6.45	-6.25±2.75
Change in CRP (mmol/l)	-0.89±2.05	-1.63±2.50	-0.02±1.64
Change in Total Cholesterol (mmol/l)	-0.23±0.45	-0.29±0.50	-0.28±0.45
Change in Triglycerides (mmol/l)	-0.49±0.49	-0.11±0.86	-0.09±0.81
Change in HDL Cholesterol (mmol/l)	0.08±0.11	0.00±0.14	0.08±0.14
Change in LDL Cholesterol (mmol/l)	-0.09±0.41	-0.25±0.70	-0.15±0.46
Change in Total Chol/HDL Ratio (mmol/l)	-0.43±0.34	-0.25±0.70	-0.48±0.49
Change in Systolic Blood Pressure (mmHg)	-5.51±6.32	0.88±5.91	-2.33±11.66
Change in Diastolic BP (mmHg)	-2.10±3.81	-0.50±4.75	-1.89±8.33
Change in MAP (mmHg)	-3.2±4.3	-0.04±4.4	-2.01±4.3
Change in Systolic Dip (%)	0±7	-4±7	-7.00±12
Change in Diastolic Nocturnal Dip (%)	-2±9	-11±10	-15±11

Table 2: Changes from baseline to 24 weeks intervention. (*CPAP = continuous positive*

airway pressure, CRP = C-reactive protein, HDL = high-density lipoproteins, LDL = low-

density lipoproteins, MAP = mean arterial pressure. Data are expressed as mean \pm SD. **Bold**

*indicates significant within-group changes, *p<0.05 vs CPAP alone)*

		Liraglutide	СРАР	Combination
AHI	Pre	54±21	48±20	48±17
	Post	42±16	3±3*	5±5*
ODI	Pre	45±22	40±17	43±17
	Post	32±19	6±11*	5±5*
TST90	Pre	14±12	17±17	11±11
	Post	7±11	0±1	1±2
Minimum SpO ₂	Pre	77±10	77±6	78±7
	Post	81±8	87±4	88±4
Baseline SpO ₂	Pre	94±1	93±2	93±1
	Post	94±1	94±2*	94±1

717 Table 3: Baseline and end-of-study obstructive sleep apnea parameters. (CPAP =

continuous positive airway pressure, AHI = apnea/hypopnea index, ODI = oxygen

desaturation index, TST90 = oxygen saturation time spent below 90% of total sleep time,

 $SpO_2 = oxygen saturation; Bold indicates p < 0.05 for within group changes, *p<0.05 vs$

Liraglutide)

724 Figure Legends

725

726	Figure 1: Representat	ive coronal oblique FDG PET maximu	um intensity projection (MIP)

- 727 images with mild, diffuse aortic wall uptake in the ascending thoracic aorta (arrows) on the
- baseline PET (A), which qualitatively resolved on the end of study PET with CPAP alone
- (B). Aortic wall target-to-background ratio (TBR) was 1.74 on the baseline PET and 1.13 on
- the end of study scan.
- 731 Figure 2: Change in vascular inflammation as measured by aortic wall target-to-background
- ratio (TBR) in the three treatment groups in A) the whole cohort (n = 30) and B) the cohort
- 733 with those using statin medication excluded (n = 21). Data represent mean±SD.
- Figure 3: Change in CT coronary artery plaque volumes from baseline to 24-week of
- 735 intervention. A) total plaque, B) calcified plaque (CP), C) non-calcified plaque (NCP) and
- 736 D) low-attenuation plaque (LD NCP)
- 737 Figure 4: Representative quantitative coronary plaque analysis in a subject assigned to CPAP

therapy alone. Images of the left anterior descending coronary artery showed a mixture of

non-calcified (yellow color overlay) and low density (red color overlay) plaque subtypes

throughout the vessel at baseline imaging (A) (total volume 625mm³) and a reduction in both

subtypes of 236mm³ at 24-week repeat coronary computed tomographic angiography

742 (CCTA) (B).

- 743 **Figure 5:** Correlations between change in CCTA plaque measurements and A) change in
- TST90, B) change in vascular inflammation as measured by aortic wall TBR, C) change in
- randothelial function as measured by RHI



749 750

747

751 Figure 1



758



C) Non-calcified Plaque Volume



Supervisional definition of the second secon

D) Low-attenuation Plaque Volume

B) Calcified Plaque Volume



759 760

60 Figure 3





Figure 4

